BAXTER INTERNATIONAL INC Q3 FY2026 earnings call

• Strategic Priorities: Management is focused on three key areas: stabilizing the business, strengthening the balance sheet, and embedding continuous improvement via Baxter GPS.
• Operational Improvements: In Q3, CCS on-time shipments improved 8% year-over-year, and Advanced Surgery quality measures improved nearly 20%. Over 700 continuous improvement initiatives have been completed YTD, including a 10% reduction in blood pressure cuff manufacturing cycle times.
• Supply Chain & Quality Actions: To address FDA warning letter observations at the Round Lake, Illinois facility, Baxter discontinued production of Cephalosporin (SEF) products. This simplifies operations, supports supply continuity for non-SEF products, and aims to streamline compliance efforts. The action resulted in $39 million in restructuring costs excluded from non-GAAP earnings.
• Financial Discipline: Free cash flow reached $448 million in Q3. The company completed a $600 million cash tender offer, retiring $864 million in debt and recognizing a pre-tax gain of £253 million on early extinguishment, advancing deleveraging toward a target net leverage ratio of approximately 3x by year-end.

Medical Products and Therapy (MPT) reported sales of $2.1 billion, representing a 6% organic increase. This segment accounted for approximately 70% of total reported revenue. Growth was driven by infusion systems (including Spectrum IQ and digital solutions), drug compounding services (up 9%), and IV solutions, partially offset by a 3% decline in injectables due to price deflation and manufacturing challenges. Advanced Surgery within MPT grew 12% organically to $342 million. Healthcare Systems and Technology (HST) reported sales of $806 million, a 4% organic increase, contributing roughly 27% of total revenue. Within HST, Care and Connectivity Solutions (CCS) grew 5% to $498 million, supported by global surgical solutions and patient support systems, while Frontline Care (FLC) grew 3% to $308 million, driven by Connex360 demand but offset by planned product exits.

• Full-Year 2026 Organic Sales: Raised to a range of 3% to 4%, up from the previous guidance of 2% to 3%.
• Full-Year 2026 Adjusted EPS: Bottom end raised to $2.05–$2.15 per diluted share (previously $1.95–$2.15).
• Full-Year 2026 Reported Sales: Expected growth of 4% to 5%, inclusive of approximately 100 basis points from foreign exchange and a ~$25 million headwind from Vantiv MSA revenues.
• Segment Outlook: MPT expected to grow low-to-mid single digits organically; HST expected to grow low single digits.
• Margins & Costs: Full-year adjusted operating margin expected at 13% to 14%. Non-operating expenses projected between £245 million and £255 million, reflecting lower interest expense post-debt reduction.
• TSA/Vantiv Reimbursements: Expected to range between $165 million and $175 million, broadly offset by related expenses, with no net contribution to earnings.
• 2027 Guidance: Not provided in this call; detailed outlook for 2027 will be presented at the Q4 earnings call in February 2027.

• Regulatory Compliance: Recent FDA warning letter regarding the Round Lake facility necessitated operational changes and discontinuation of SEF products to address quality observations.
• Product Discontinuation Impact: Stopping CEFA production removes an estimated $50 million in top-line sales and $30 million in operating income for 2026, though offsets are anticipated through inventory roll-through and alternative products.
• Macroeconomic Headwinds: Potential impacts from inflationary pressures (salary, electronics, materials), tariffs, and hospital capital spending constraints due to interest rates.
• Supply Chain Dependencies: Ongoing reliance on contract manufacturers and risks associated with competitor supply issues creating both opportunities and vulnerabilities.
• Integration and Execution Risks: Challenges in standardizing processes, reducing embedded organizational complexity, and successfully integrating acquired assets or managing TSA wind-downs.

Q: Analyst asked about the rationale for discontinuing Cephalosporin (SEF) products, the financial impact ($50M rev/$30M op income loss in 2026), and whether this creates a 2% EPS headwind for 2027.

A: CEO explained the decision simplifies Round Lake operations for non-SEF production, improving supply resiliency and helping address FDA warning letter issues. While acknowledging the financial impact, he noted mitigating factors like inventory roll-through and alternative products would offset some losses, preventing a direct full-flow-through to 2027 EPS.

Q: Analyst inquired about M&A strategy, asking if management is pursuing acquisitions given the focus on deleveraging and capital allocation.

A: CEO outlined a disciplined four-pillar approach: strategic rationale (tech/geography), market expansion, integration capability (GPS enablement), and financial return (ROIC/margins). He emphasized that M&A is contingent on achieving a net leverage ratio of ~3x by year-end, after which the company can pursue 'tuck-in' acquisitions to support long-term growth in areas like cardiac monitoring and advanced surgery.

Q: Analyst asked about the sustainability of Q3's mid-single-digit top-line growth into Q4 and the magnitude of margin headwinds in 2027 from TSA, tariffs, and product exits.

A: IR confirmed Q4 expectations align with Q3 performance, citing favorable comps ending and continued strength in advanced surgery and drug compounding. CFO noted significant margin headwinds in 2027 (inflation, tariffs, TSA exit, product exits) but highlighted strong visibility into cost-saving pipelines and efficiency programs designed to neutralize these pressures, promising detailed puts-and-takes in February.

Q: Analyst asked what is driving the double-digit acceleration in Advanced Surgery and if it is sustainable despite difficult comps.

A: CEO attributed growth to fundamental market expansion, successful global execution, and capturing market share from a competitor facing supply challenges. He acknowledged tougher year-over-year comparisons for 2027 but expressed confidence in the team’s ability to maintain momentum by closely monitoring competitor supply dynamics.

Q: Analyst sought clarity on macro cost pressures (oil, freight, materials) for 2027 and how they compare to prior updates.

A: CFO identified salary inflation, electronics, and materials as primary drivers, with energy/freight being secondary. He stated that while inflation is stepping up slightly, the company has successfully offset 2026 pressures with efficiency savings and expects similar proactive mitigation in 2027. CEO added that kidney care divestiture reduced exposure to fuel/oil costs.